Safety and Efficacy of Combigan® Ophthalmic Solution in Korea
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01987752|
Recruitment Status : Completed
First Posted : November 19, 2013
Results First Posted : April 4, 2014
Last Update Posted : April 4, 2014
|Condition or disease||Intervention/treatment|
|Glaucoma, Open-Angle Ocular Hypertension||Drug: brimonidine tartrate/timolol maleate Ophthalmic Solution|
|Study Type :||Observational|
|Actual Enrollment :||732 participants|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||November 2011|
|Actual Study Completion Date :||November 2011|
Combigan® Ophthalmic Solution
Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.
Drug: brimonidine tartrate/timolol maleate Ophthalmic Solution
brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
Other Name: Combigan®
- Percentage of Participants Reporting Adverse Events [ Time Frame: Up to 2.6 Years ]An adverse event was any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.
- Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP) [ Time Frame: Baseline, Week 4 ]IOP is a measurement of the fluid pressure inside the eye. The study doctor classified the overall improvement of the IOP change from Baseline into 3 categories: Improvement (effective), No Change or Exacerbation (ineffective). The percentage of participants with Improvement is reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01987752
|Korea, Republic of|
|Seoul, Korea, Republic of|
|Study Director:||Medical Director||Allergan|